Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Authors :: Sancho JM
Navarro B
Soler Campos JA
de Oteyza JP
de Barrenetxea Lekue C
Bregni M
Grasso Cicala S
Spione M
Mombiedro C
Soler B
Zinzani PL
Source :: European Journal of Haematology, r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, Universidad de Alicante (UA)
Publication Year :: 2020
Publisher :: Blackwell Publishing Inc., 2020.
Abstract: Few treatment options exist for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who fail first- and second-line therapies. Pixantrone is a novel aza-anthracenedione agent with reduced potential for cardiotoxicity but maintained anti-tumour activity relative to anthracyclines. The current retrospective, observational, real-life study was undertaken in 79 patients who received pixantrone monotherapy for multiply R/R aggressive B-cell NHL in Spain and Italy.

Subjects :: immune system diseases
hemic and lymphatic diseases
aggressive B-cell lymphoma, pixantrone, relapse, survival

ISSN :: 09024441
Database :: OpenAIRE
Journal :: European Journal of Haematology, r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, Universidad de Alicante (UA)
Accession number :: edsair.dedup.wf.001..9fc74b910479ad073958dcfd081e54ee

Tools